Zobrazeno 1 - 10
of 141
pro vyhledávání: ''
Autor:
Waleed S. Al Amri, William E. Hughes, James L. Thorne, Geoff Wells, Ian M. Carr, Brian V Hogan, Thomas A. Hughes, Fiona Langlands, Arindam Pramanik, Layla K. Younis, Stacey J. Jones, Sarah A. Harris, Eldo T. Verghese, Rebecca Millican-Slater, Nevine M.F. El Deeb, Mervat A. Hamza, Baek Kim, Noha Gwili
Publikováno v:
British Journal of Cancer
Background Breast cancer stem cells (BCSCs) are drivers of therapy-resistance, therefore are responsible for poor survival. Molecular signatures of BCSCs from primary cancers remain undefined. Here, we identify the consistent transcriptome of primary
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99a64defdd7881cec05092b3963a5ac9
https://eprints.whiterose.ac.uk/174958/7/s41416-021-01484-w.pdf
https://eprints.whiterose.ac.uk/174958/7/s41416-021-01484-w.pdf
Autor:
Nelofar Nargis, Gunjan Mandal, Samir Jana, Thomas A. Hughes, Soumya Chatterjee, Annesha Chatterjee, Laura M. Wastall, Himansu Roy, Arindam Bhattacharyya
Publikováno v:
British Journal of Cancer
BACKGROUND: Cancer-associated fibroblasts (CAFs) are known to impact on tumour behaviour, but the mechanisms controlling this are poorly understood. METHODS: Breast normal fibroblasts (NFs) or CAFs were isolated from cancers by laser microdissection
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::957384df57b4414e3eef66fa38c6c18b
https://eprints.whiterose.ac.uk/149993/8/s41416-019-0566-7.pdf
https://eprints.whiterose.ac.uk/149993/8/s41416-019-0566-7.pdf
Publikováno v:
Breast Cancer Research : BCR
We read with interest the recent article by Roth and colleagues [1] reporting the findings of altered tumorspecific microRNAs (miRNAs) in sera of breast cancer patients. This report further substantiates emerging data suggesting that blood-based miRN
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e37de41d6ad927b9cb6665402fe5e878
http://hdl.handle.net/10379/11894
http://hdl.handle.net/10379/11894
Autor:
Qiongchao Jiang, Bing Ou, Fengtao Liu, Jiyi Yao, Hui Zhi, Shao-Yun Hao, Xin Pan, Xiao-yun Xiao, Zizhuo Zhao, Bao-Ming Luo
Publikováno v:
Breast Cancer (Tokyo, Japan)
Background There is an unmet need for specific and sensitive imaging techniques to assess the efficacy of breast cancer therapy, particularly Her-2-expressing cancers. Ultrasonic microbubbles are being developed for use as diagnostic and therapeutic
Autor:
Reiner Laus, Lisa Do, John R. Lombardo, Ulrike Dirmeier, Katie Dalpozzo, Alain Delcayre, Peter L. Schoonmaker, Ryan Rountree, Robin Steigerwald, Stefanie Mandl, Thierry Giffon
Publikováno v:
Cancer Immunology, Immunotherapy
MVA-BN®-HER2 is a new candidate immunotherapy designed for the treatment of HER-2-positive breast cancer. Here, we demonstrate that a single treatment with MVA-BN®-HER2 exerts potent anti-tumor efficacy in a murine model of experimental pulmonary m
Autor:
Mel Fox, Gary C. Starling, Mian Su, Sonia Tanlimco, Debra Chao, Shiming Ye, Donghee Choi, Johnny Yin, Lisa Durkin, Patricia Culp, Yongke Zhang, Eric D. Hsi, Mien Sho, Han Kim
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Background The receptor for the cytokine TWEAK (TweakR) is a cell surface member of the tumor necrosis factor receptor superfamily with diverse biological roles. TNFRSF family members are appealing therapeutic targets in oncology due to their aberran
Autor:
Gunnar Mellgren, Sara Gandini, Andrea Decensi, Jennifer Gjerde, Aliana Guerrieri-Gonzaga, Line L. Haugan Moi, Ernst A. Lien, Valentina Aristarco
Publikováno v:
Breast Cancer Research and Treatment
Tamoxifen dosage is based on the one-dose-fits-all approach. The anticancer effect of tamoxifen is believed to be due to the metabolites, 4-hydroxytamoxifen (4OHtam), and 4-hydroxy-N-desmethyltamoxifen (4OHNDtam/endoxifen). These demethylated metabol
Autor:
Marie K. Kirby, Jason Gertz, Amy S. Nesmith, William E. Grizzle, Nicholas S. Davis, Patsy G. Oliver, Kevin M. Bowling, Katherine E. Varley, Albert F. LoBuglio, Richard M. Myers, Brian S. Roberts, Andres Forero, Donald J. Buchsbaum
Publikováno v:
Breast Cancer Research and Treatment
Read-through fusion transcripts that result from the splicing of two adjacent genes in the same coding orientation are a recently discovered type of chimeric RNA. We sought to determine if read-through fusion transcripts exist in breast cancer. We pe
Publikováno v:
Breast Cancer Research and Treatment
There is a growing belief that the metabolic program of breast tumor cells could be a therapeutic target. Yet, without detailed information on central carbon metabolism in breast tumors it is impossible to know which metabolic pathways to target, and
Autor:
Melissa A. Troester, Olga Karginova, Erick Roman, Charles M. Perou, Aleix Prat, Xiaping He, Cheng Fan, Barbara Adamo, J. Chuck Harrell, Joel S. Parker, Lisa M. Bixby
Publikováno v:
Breast Cancer Research and Treatment
Five molecular subtypes (luminal A, luminal B, HER2-enriched, basal-like, and claudin-low) with clinical implications exist in breast cancer. Here, we evaluated the molecular and phenotypic relationships of (1) a large in vitro panel of human breast